Latest From Qiagen NV
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week, FDA approved Qiagen's therascreen FGFR RGQ RT-PCR companion diagnostic for Janssen's new drug to treat specific types of urothelial cancer and Intact Vascular's Tack device to treat dissections of the above-the-knee peripheral arteries following angioplasty.
The Therascreen FGFR kit helps identify urothelial tumors with alterations to the fibroblast growth factor receptor 3 gene that indicate the cancer will respond to Janssen’s new drug Balversa.
Zimmer Biomet announced 510 (k) clearance for its Rosa Knee system for robotically assisted total knee replacement surgery.
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker.
Drug Discovery Tools
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Qiagen NV
- Senior Management
Peer M Schatz, CEO
Roland Sackers, CFO
Manuel O Mendez, SVP, Global Commercial Ops.
- Contact Info
Phone: (31) 77 3556600
Venlo, 5912 PL
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.